focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
6th Dec 20182:59 pmRNSDirector/PDMR Shareholding
23rd Nov 20185:04 pmRNSHalf-year Report
19th Oct 20185:18 pmRNSH1 Trading Update
4th Sep 20188:00 amRNSCompletion of Share Buyback
30th Aug 20187:00 amRNSProposed Share Buyback
7th Aug 20185:48 pmRNSTransaction in Own Shares
7th Aug 20187:00 amRNSTransaction in Own Shares
1st Aug 20186:06 pmRNSTransaction in Own Shares
31st Jul 20186:02 pmRNSTransaction in Own Shares
26th Jul 20185:59 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
11th Jul 20185:33 pmRNSTransaction in Own Shares
20th Jun 20187:05 amRNSPublication of Annual Report and Accounts
20th Jun 20187:00 amRNSFinal Results
13th Jun 20185:07 pmRNSTransaction in Own Shares
6th Jun 20188:04 amRNSTransaction in Own Shares
20th Apr 20184:35 pmRNSTrading Statement
12th Apr 20185:21 pmRNSTransaction in Own Shares
6th Apr 20185:47 pmRNSTransaction in Own Shares
5th Apr 20182:16 pmRNSTransaction in Own Shares
29th Mar 20186:25 pmRNSDirector/PDMR Shareholding
29th Mar 20186:21 pmRNSDirector/PDMR Shareholding
29th Mar 20181:32 pmRNSLaunch of two new automated assays
29th Mar 20187:00 amRNSTransaction in Own Shares
26th Mar 20185:08 pmRNSTransaction in Own Shares
23rd Mar 20183:59 pmRNSTransaction in Own Shares
21st Mar 20185:50 pmRNSDirectorate Change
21st Mar 20181:08 pmRNSDirector/PDMR Shareholding
1st Mar 20184:50 pmRNSTransaction in Own Shares
22nd Feb 20185:02 pmRNSTransaction in Own Shares
21st Feb 20185:30 pmRNSTransaction in Own Shares
15th Feb 20185:20 pmRNSTransaction in Own Shares
13th Feb 201812:13 pmRNSTransaction in Own Shares
12th Feb 20181:22 pmRNSTransaction in Own Shares
6th Feb 20184:49 pmRNSTransaction in Own Shares
5th Feb 20183:19 pmRNSTransaction in Own Shares
2nd Feb 20182:47 pmRNSTransaction in Own Shares
24th Jan 20181:21 pmRNSTransaction in Own Shares
16th Jan 20187:00 amRNSPartnership Agreement with Technogenetics
15th Jan 20184:45 pmRNSTransaction in Own Shares
27th Dec 20175:16 pmRNSTransaction in Own Shares
24th Nov 20174:30 pmRNSHalf-year Report
23rd Nov 20175:15 pmRNSTransaction in Own Shares
14th Nov 201712:06 pmRNSTransaction in Own Shares
13th Nov 20175:37 pmRNSTransaction in Own Shares
2nd Nov 20176:05 pmRNSTransaction in Own Shares
1st Nov 20174:29 pmRNSAdditional Listing
1st Nov 20174:05 pmRNSTransaction in Own Shares
31st Oct 20176:22 pmRNSDirectorate Change
31st Oct 20176:03 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.